IL-36 Reporter HEK 293 Cells
|HEK-Blue™ IL-36 Cells||Unit size||Cat. code||Docs||Qty||Price|
Human IL-36 Reporter Cells
3-7 x 10e6 cells
Interleukin-36 Reporter Cells
HEK-Blue™ IL-36 cells were engineered from the human embryonic kidney HEK 293 cell line to detect bioactive interleukin-36 (IL-36) by monitoring the activation of NF-κB/AP-1 pathways. Three isoforms, IL-36α, IL-36β, and IL-36γ, mediate pro-inflammatory functions, while a fourth one, IL-36Ra, acts as an antagonist [1,2].
Cell line description:
HEK-Blue™ IL-36 cells were generated by stable overexpression of the genes encoding for the human IL-36R (IL-1R6), human IL-1RAcP, and an NF-κB/AP-1-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. NF-κB/AP-1-dependent SEAP activity is readily assessable in the supernatant using QUANTI-Blue™ Solution, a detection reagent. Of note, HEK-Blue™ IL-36 cells maintain their responses to other cytokines that signal through NF-κB/AP-1, such as hIL-1β and hTNF-α (see figures).
Features of HEK-Blue™ IL-36 cells:
- Fully functional IL-36 signaling pathway
- Readily assessable NF-κB/AP-1-inducible SEAP reporter activity
- The stability for 20 passages has been verified
- Functionally tested and guaranteed mycoplasma-free
Applications of HEK-Blue™ IL-36 cells:
- Detection of human IL-36α and IL-36γ (3 pg/ml - 10 ng/ml)
- Detection of human IL-36β (1 ng/ml -10 ng/ml)
- Screening of anti-IL-36 and anti-IL-36R antibodies
1. Buhl A-L. & Wenzel J., 2019. Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol. 10:1162.
2. Zhou L. & Todorovic V., 2021. Interleukin-36: Structure, Signaling and Function. Adv Exp Med Biol. 21:191-210.
Human IL-36R mRNA expression in HEK-Blue™ IL-36 cells.
Total mRNA was extracted from ~1x106 HEK-Blue™ parental cells (blue) and HEK-Blue™ IL-36 cells (red). Human IL-36R mRNA was amplified using quantitative RT-qPCR.
Data are represented as the log2 fold change comparing hIL-36R relative expression between the two cell lines.
Dose-response of HEK-Blue™ IL-36 cells to recombinant IL-36.
Cells were stimulated with increasing concentrations of recombinant human IL-36 (hIL-36) and murine IL-36 (mIL-36) isoforms α, β, or γ. After overnight incubation, the NF-κB response was determined using QUANTI‑Blue™ Solution, a SEAP detection reagent. The optical density (OD) at 630 nm is shown as mean ± SEM.
Response of HEK-Blue™ IL-36 cells to a panel of cytokines.
Cells were stimulated with various human and murine recombinant cytokines: 0.01 ng/ml hIL-36α, 1 ng/ml hIL-36β, 0.01 ng/ml hIL-36γ, 1 ng/ml mIL-36α, 0.003 ng/ml hIL-1β, 0.1 ng/ml TNF-α, or 1000 U/ml hIFN-α. After overnight incubation, SEAP activity was assessed using QUANTI‑Blue™ Solution. The optical density (OD) at 630 nm is shown as mean ± SEM.
Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™
Specificity: human IL-36α, IL-36β and IL-36γ
- 3 pg/ml - 10 ng/ml for hIL-36α and hIL-36γ
- 1 ng/ml - 10 ng/ml for hIL-36β
- NF-κB/AP-1-dependent SEAP reporter activity in response to human IL-36 isoforms α, β, and γ has been validated.
- The expression of human IL-36R has been confirmed by RT-qPCR.
- The stability for 20 passages, following thawing, has been verified.
- These cells are guaranteed mycoplasma-free.
This product is covered by a Limited Use License (See Terms and Conditions).Back to the top
- 3-7 x 106 HEK-Blue™ IL-36 cells in a cryovial or shipping flask
- 1 ml Normocin™ (50 mg/ml)
- 1 ml Blasticidin™ (10 mg/ml)
- 1 ml Zeocin® (100 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent).
Shipped on dry ice (Europe, USA, Canada and some areas in Asia)Back to the top
The cytokine interleukin 36 (IL-36) belongs to the IL-1 superfamily. Three isoforms, IL-36α, IL-36β, and IL-36γ, mediate pro-inflammatory functions, while a fourth one, IL-36Ra, acts as an antagonist [1,2]. IL-36 signalization requires the formation of a complex comprised of the IL-36 receptor (IL-36R or IL-1R6) and the IL-1 receptor accessory protein (IL-1RAcP). The binding of agonist ligands to the IL-36R allows the recruitment of IL-1RAcP and the production of pro-inflammatory cytokines and chemokines through the activation of NF-κB and AP-1 [1,2]. The IL-36Ra antagonist inhibits the signaling by binding to IL-36R and preventing the recruitment of IL-1RAcP [1,2]. IL-36 associated immune response mainly takes place in barrier tissues, such as the skin, lungs, and intestines. Dysregulation of IL-36 isoform expression and signaling has been associated with inflammatory diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease [1,2].
1. Buhl A-L. & Wenzel J., 2019. Interleukin-36 in infectious and inflammatory skin diseases. Front. Immunol. 10(1162). doi: 10.3389/fimmu.2019.01162.
2. Zhou L. & Todorovic V., 2021. Interleukin-36: Structure, Signaling and Function. Protein Reviews: Volume 21. doi: 10.1007/5584_2020_488.